Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation and Depletion (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Depreciation and Depletion for 3 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion changed 0.0% to $600000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 4.17% increase, with the full-year FY2025 number at $2.5 million, up 4.17% from a year prior.
  • Depreciation and Depletion was $600000.0 for Q4 2025 at Artiva Biotherapeutics, down from $700000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $700000.0 in Q3 2025 to a low of $500000.0 in Q2 2023.
  • A 3-year average of $600000.0 and a median of $600000.0 in 2023 define the central range for Depreciation and Depletion.
  • Biggest YoY gain for Depreciation and Depletion was 20.0% in 2024; the steepest drop was 0.0% in 2024.
  • Artiva Biotherapeutics' Depreciation and Depletion stood at $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Depreciation and Depletion are $600000.0 (Q4 2025), $700000.0 (Q3 2025), and $600000.0 (Q2 2025).